Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 128Recruiting 57Active not recruiting 39Terminated 38Unknown 13Not yet recruiting 5Withdrawn 4Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Fluorodeoxyglucose F18 3pembrolizumab 2sacituzumab govitecan 1ibrutinib 1erdafitinib 1enzalutamide 1enfortumab vedotin 1dynorphin-converting endopeptidase 1avelumab 1apixaban 1Vinblastine 1Surveys and Questionnaires 1Specimen Handling 1Radiosurgery 1Pancreatectomy 1Paclitaxel 1Nivolumab 1Methotrexate 1Magnetic Resonance Imaging 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Health Information Exchange 1Genetic Testing 1Genetic Counseling 1Gemcitabine 1Focus Groups 1Enoxaparin 1Docetaxel 1Cystoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × enzalutamide × Genitourinary × Clear all
NCT04145375 2026-05-08

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Zenith Epigenetics

Phase 1/2 Enrolling by invitation
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡